WAveCrest Vs. Watchman TranssEptal LAA Closure to REduce AF-Mediated STroke 2

PHASE3TerminatedINTERVENTIONAL
Enrollment

248

Participants

Timeline

Start Date

December 27, 2017

Primary Completion Date

December 21, 2023

Study Completion Date

December 21, 2023

Conditions
Stroke
Interventions
DEVICE

Coherex WaveCrest® Left Atrial Appendage Occlusion System

Percutaneous left atrial appendage closure

DEVICE

Watchman® LAA Closure Device

Percutaeous left atrial appendage closure

Trial Locations (25)

2023

St. Vincent's Hospital, Sydney

10016

New York University- NYU Langone Cardiac, New York

New York University, New York

10029

Icahn School of Medicine at Mount Sinai, New York

11706

Northwell Health, Bay Shore

17104

UPMC Pinnacle Health Cardiovascular Institute, Harrisburg

20010

Medstar Heart and Vascular Institute - Washington Hospital Center, Washington D.C.

21218

MedStar Union Memorial Hospital, Baltimore

23298

Virginia Commonwealth University, Richmond

30060

Wellstar Kennestone, Marietta

30309

Piedmont Heart Institute, Atlanta

32204

St. Vincent's Medical Center, Jacksonville

35243

Grandview Medical Center, Birmingham

38801

Cardiology Associates Research, LLC, Tupelo

40503

Baptist Health Lexington, Lexington

43210

Ohio State University, Columbus

49684

Munson Medical Center, Traverse City

49855

Marquette General Hospital, Marquette

75093

Heart Hospital Baylor Plano (Baylor Research Institute), Plano

75702

Christus Trinity Clinic Research, Tyler

76104

Baylor Scott & White All Saints Medical Center, Fort Worth

78705

Texas Cardiac Arrhythmia Research Foundation, Austin

85224

Dignity Health Mercy Gilbert Medical Center, Chandler

90033

Pacific Heart Institute / St. John's Health Center, Los Angeles

Unknown

Monash Health, Melbourne

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Biosense Webster, Inc.

INDUSTRY

lead

Coherex Medical

INDUSTRY